Peifen Fu
Impact in
- Cancer Research top 2%
- Cancer-related molecular mechanisms research
- MicroRNA in disease regulation
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cancer Cells and Metastasis
Papers in
-
- Cancer-related molecular mechanisms research 15
- MicroRNA in disease regulation 10
- Breast Cancer Treatment Studies 10
-
- Circular RNAs in diseases 7
- RNA Research and Splicing 6
- RNA modifications and cancer 6
- Co-authors
- Weiyang Lou (7 shared papers)Minya Yao (15 shared papers)Bisha Ding (4 shared papers)Kezhen Lv (8 shared papers)Chengyong Du (8 shared papers)Haiyan Wei (5 shared papers)Yaomin Chen (5 shared papers)Feiya Du (6 shared papers)
- Journals
- Breast Cancer (4 papers)Frontiers in Oncology (3 papers)Journal of Zhejiang University SCIENCE B (2 papers)Cell Death and Disease (2 papers)Journal of Clinical Oncology (2 papers)
- Partner nations
- ChinaUnited StatesJapan
In The Last Decade
Peifen Fu
51 papers receiving 1.6k citations
Peers
Comparison fields: 5 of 102
- Cancer Research 856
- Oncology 428
- Molecular Biology 1.1k
- Immunology 185
- Cell Biology 115
Countries citing papers authored by Peifen Fu
This map shows the geographic impact of Peifen Fu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peifen Fu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peifen Fu more than expected).
Fields of papers citing papers by Peifen Fu
This network shows the impact of papers produced by Peifen Fu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peifen Fu. The network helps show where Peifen Fu may publish in the future.
Co-authors
The 25 scholars most cited alongside Peifen Fu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 54 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 141 | |
| 2 | 2016 | 116 | |
| 3 | 2020 | 114 | |
| 4 | 2018 | 111 | |
| 5 | 2017 | 78 | |
| 6 | 2016 | 77 | |
| 7 | 2017 | 73 | |
| 8 | 2012 | 63 | |
| 9 | 2016 | 47 | |
| 10 | 2019 | 46 | |
| 11 | 2020 | 42 | |
| 12 | 2014 | 41 | |
| 13 | 2019 | 38 | |
| 14 | 2013 | 38 | |
| 15 | 2023 | 38 | |
| 16 | 2012 | 35 | |
| 17 | 2011 | 33 | |
| 18 | 2013 | 33 | |
| 19 | WP1130 increases cisplatin sensitivity through inhibition of usp9x in estrogen receptor-negative breast cancer cells. | 2017 | 30 |
| 20 | 2014 | 29 |
About Peifen Fu
Peifen Fu is a scholar working on Cancer Research, Molecular Biology, Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine, having authored 54 papers that have together received 1.6k indexed citations. Recurring topics across this work include Cancer-related molecular mechanisms research (15 papers), MicroRNA in disease regulation (10 papers), Breast Cancer Treatment Studies (10 papers), Circular RNAs in diseases (7 papers), Cancer Cells and Metastasis (6 papers), HER2/EGFR in Cancer Research (6 papers), RNA Research and Splicing (6 papers) and RNA modifications and cancer (6 papers). The work is most often cited by research in Cancer Research (856 citations), Oncology (428 citations), Molecular Biology (1.1k citations), Immunology (185 citations) and Cell Biology (115 citations). Peifen Fu has collaborated with scholars based in China, United States and Japan. Frequent co-authors include Weiyang Lou, Minya Yao, Bisha Ding, Kezhen Lv, Chengyong Du, Haiyan Wei, Yaomin Chen, Feiya Du, Bajin Wei and Yu Liu. Their work appears in journals such as Breast Cancer, Frontiers in Oncology, Journal of Zhejiang University SCIENCE B, Cell Death and Disease and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.